12/23
07:11 am
dnth
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
Medium
Report
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
12/23
06:00 am
dnth
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
Medium
Report
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
12/22
08:37 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $46.00 price target on the stock.
Medium
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $46.00 price target on the stock.
12/7
02:49 am
dnth
Ashland, Bitdeer, and More Stocks See Action From Activist Investors [Yahoo! Finance]
Low
Report
Ashland, Bitdeer, and More Stocks See Action From Activist Investors [Yahoo! Finance]
11/24
07:00 am
dnth
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
11/10
08:03 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
11/7
07:07 pm
dnth
Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
11/6
08:40 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.
Medium
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.
11/5
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Medium
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
11/4
08:00 am
dnth
Dianthus Therapeutics to Participate in Four Investor Conferences During November
Low
Report
Dianthus Therapeutics to Participate in Four Investor Conferences During November
10/29
03:30 pm
dnth
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Low
Report
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
10/16
11:40 pm
dnth
Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion [Yahoo! Finance]
Low
Report
Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion [Yahoo! Finance]
10/16
07:00 am
dnth
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Low
Report
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
10/14
09:12 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $56.00 price target on the stock.
Medium
Report
Dianthus Therapeutics (NASDAQ:DNTH) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $56.00 price target on the stock.
10/2
08:05 am
dnth
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting [Yahoo! Finance]
10/2
08:00 am
dnth
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Medium
Report
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
9/30
12:02 pm
dnth
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target [Yahoo! Finance]
Low
Report
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target [Yahoo! Finance]